BeiGene announced that the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across three indications, including first- and second-line use. “Tislelizumab is foundational for BeiGene’s solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which there remains a significant unmet need at all stages of the disease,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “Today’s EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union. Second-line use in ESCC was also approved just weeks ago by the U.S. Food and Drug Administration, putting us well on our way to fulfilling our commitment to bring this innovative therapy to many more patients around the world.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE:
- Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
- BeiGene price target lowered to $164.30 from $179.30 at BofA
- BeiGene price target lowered to $161 from $196 at Bernstein
- BeiGene Announces Executive Team Reshuffle and Director Pay Revision
- JPMorgan biotech/pharma analysts hold an analyst/industry conference call